Julieth Lalashowi
Mbeya,Tanzania
Summary
Medical Doctor and Clinical Researcher specialising in tuberculosis clinical trials and post-TB sequelae. Proven experience in coordinating research studies, ensuring participant safety, and implementing effective clinical trial protocols. Currently pursuing a PhD to investigate cardiovascular outcomes among post-tuberculosis patients,
contributing to advancements in evidence-based care
Overview
9
9
years of professional experience
11
11
years of post-secondary education
Work history
Research scientist
National Institute for Medical Research, Mbeya
Mbeya
2019.11 - Current
- 2025-to date, Principal Investigator: A Confirmatory Randomized Controlled Trial of Adjunctive N-acetylcysteine to Prevent Post Tuberculosis Lung Disease (NAC-PTLD) A TB SEQUEL II substudy
- 2025 to date, sub Investigator: Platform Assessing Regimens And Durations In a Global Multisite consortium for TB. A Seamless Phase 2B/2C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis
- 2024-to date, Clinical study coordinator: Post TB Lung Disease: Assessing long term morbidity and mortality and associated risk factors
- 2024-2026, Sub Investigator and Acting site Principal Investigator when need: A novel four months regimen targetting both the host and microbe, panTB HM study
- 2024-2026, sub Investigator: A multiple arm, multiple stage (MAMS), phase 2B/C, open label, randomized, controlled platform trial to evaluate experimental arms including an increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis
- 2023-2024,Sub Investigator: A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and ExposureResponse Relationship of different doses of BTZ-043 in combination with Bedaquiline and Delamanid in Adult Subjects with Newly Diagnosed, Uncomplicated, Drug-sensitive Pulmonary Tuberculosis
- 2023-to date, sub Investigator: Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infection in Patients with Diabetes Mellitus
- 2021-2024, Clinical study coordinator: Community and Universal Testing for TB among contacts (CUT-TB)
- 2021-2022, Sub Investigator , a phase IIb, open label, randomized controlled, dose Ranging Multicenter trial to evaluate the safety, tolerability, pharmacokinetics and exposure Response relationship of deifferent doses of Sutezolid in combination with bedaquilline, Delamanid and Moxifloxacin in Adult subjects with newly diagnosed,uncomplicated, smear-Positive, Drug sensitive Pulmonary TB.
- 2021-2022, Sub Investigator, Study sub-investigator; A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of different doses of Delpazolid in combination with Bedaquiline, Delamanid and Moxifloxacin in Adult Subjects with Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary Tuberculosis.
- 2020-2023, Clinical study coordinator: (R)emoved (I)njectable modified (S)hort – course regimens for (E)Xpert Multidrug Resistant Tuberculosis: Feasibility and Effectiveness of the modified shorter duration injectable-free Multidrug Resistant (MDT-TB) regimen in RR/MDR TB population in the Tanzania
- 2019-2022, clinical study coordinator:A prospective randomized controlled trial of adjunctive N-acetylcysteine (NAC) in adult
patients with pulmonary tuberculosis: a sub-study of TB-SEQUEL
- 2019-2022, clinical study coordinator: Pathogenesis and risk factors of long-term sequelae of pulmonary TB defining individual outcomes and public health impact
- 2019-2021, sub Investigator: A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of H56:IC31 in Reducing the rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis
- 2019-2020, sub Investigator: An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants with Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)
Intern doctor
Mbeya Zonal Referral Hospital
Mbeya
2017.11 - 2018.11
Education
A-Levels -
Kilakala girls secondary school
Morogoro, Tanzania 2010.04 - 2012.02
Doctor of Medicine - Medicine
Kilimanjaro Christian Medical University Colledge
Moshi, Tanzania 2012.10 - 2017.10
Master of Science - Public Health
University of South Wales
2019.05 - 2023.01
Doctor of Philosophy - Medical Research in International Health
Ludwig Maximillian University (LMU)
Munich, Germany 2023.10 -
Skills
Clinical Research and Trial Coordination
Scientific Documentation and Reporting using Microsoft Word
Microsoft Office Suite Proficiency (Word, Excel, PowerPoint)
Echocardiography Imaging and Interpretation
PATS-Certified Spirometry Trainer (ToT)
Accomplishments
1. Ntshiqa T, Fasanmi A, Nagudi J, Tsope L, Copas A, Stender S, Sabi I, Ntinginya EN, Lalashowi J, Matete M, Budiaki L, Mahlalela M, Kisinda A, Mudzengi D, Minja LT, Chirwa T, Lönnroth K, Niemann S, Dreyer V, Charalambous S, Velen K, Hamada Y, Rangaka M. Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings. PLoS One. 2025;20(9):e0332125. PubMed Central PMCID: PMC12448356
2. Ntshiqa T, Nagudi J, Hamada Y, Copas A, Stender S, Sabi I, Ntinginya EN, Lalashowi J, Matete M, Ntshamane K, Morojele I, Ngobeni M, Mudzengi D, Minja LT, Chirwa T, Lönnroth K, Dreyer V, Niemann S, Rangaka M, Charalambous S, Velen K. Risk Factors Associated With Tuberculosis Infection Among Household Contacts of Patients With Microbiologically Confirmed Pulmonary Tuberculosis in 3 High Tuberculosis Burden Countries. J Infect Dis. 2025 Sep 15;232(3):e448-e458.
PubMed Central PMCID: PMC12455307.
3. Wallis RS, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G. Adjunctive NAcetylcysteine and Lung Function in Pulmonary Tuberculosis. NEJM Evid. 2024 Sep;3(9):EVIDoa2300332. PubMed PMID: 39189858.
4. Chipinduro M, Ramgi P, Lalashowi J, Belay L, Megersa SW, Chala T, Ejigu D, Abera E, Mohan S, Montgomery M, Veliaminova L, Chiumya G, Borova A, Valiyakath V, Froeschl G. Proceedings from the CIH(LMU) 2025 symposium: the role of artificial intelligence in health systems strengthening to achieve One Health. BMC Proc. 2026 Apr 29;20(Suppl 19) PubMed Central PMCID: PMC13126755.
5. Mudzengi D, Mashatole S, Xiang Q, Adrion C, Glover N, Ngwanto T, Mdluli J, Boniface S, Rassool M, Matome B, Paramo L, Svensson E, Fasanmi A, Angelo S, Moyo M, Marx C, Khosa C, Mokaba L, Mofokeng N, Lalashowi J, Nacy C, Charalambous S, Fumane E, Maphossa V, Beattie T, Brumskine W, Venter C, Mapamba D, Heinrich N, Rajaram S, Kooverjee S, Botha L, Nell M, Easton A, Foraida S, Warren RM, Sabi I, Ntinginya N, Wallis RS. panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe. Trials. 2026 Feb 27;27(1) PubMed Central PMCID: PMC13049951.
6. Mapamba DA, Sabi I, Lalashowi J, Sauli E, Buza J, Olomi W, Mtafya B, Kibona M, Bakuli A, Rachow A, Velen K, Hoelscher M, Ntinginya NE, Charalambous S, Churchyard G, Wallis RS. N-acetylcysteine modulates markers of oxidation, inflammation and infection in tuberculosis. J Infect. 2025 Feb;90(2):106379. PubMed PMID: 39756697.
7. Wenzel R, Siyame E, Ivanova O, Bakuli A, Lalashowi J, Zekoll FC, Hoelscher M, Sabi I, Rachow A, Ntinginya NE. Spirometric reference equations and lung function testing in adults from Southwestern Tanzania. IJTLD Open. 2024 Oct;1(10):473-479. PubMed Central PMCID: PMC11467849.
8. Moyo M, Ntshiqa T, Hamada Y, Copas A, Sabi I, Ntinginya EN, Lalashowi J, Matete M, Kubeka G, Tsope L, Mukora R, Mudzengi D, Nielson T, Lönnroth K, Niemann S, Rangaka M, Velen K, Charalambous S, Stender S, Minja LT. Community and Universal Testing for TB among close contacts of microbiologically confirmed pulmonary TB patients in two high TB burden countries: a protocol for a pragmatic cluster-randomised control trial. Trials. 2025 Aug 11;26(1):285. PubMed Central
PMCID: PMC12341147.
9. Mapamba DA, Sauli E, Lalashowi J, Buza J, John J, Mwaisango Z, Tarmo P, Sabi I, Rachow A, Ntinginya NE, Mtafya B. Performance of Tuberculosis Molecular Bacterial Load Assay Compared to Alere TB-LAM in Urine of Pulmonary Tuberculosis Patients with HIV Co-Infections. Int J Mol Sci. 2023 Feb 13;24(4) PubMed Central PMCID: PMC9965206
10. Borges Á, Russell M, Tait D et al. Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet Infectious Diseases, 2025; 25, 751-763
11. Lalashowi J, Mvungi H, Mwaisango Z, et alPatients’ acceptability, adherence and satisfaction on the modified shorter all-oral multidrug-resistant tuberculosis regimen: a two-phase cross-sectional study in TanzaniaBMJ Open 2025;15:e088556. doi: 10.1136/bmjopen-2024-088556
12. Ivanova, O., Sineke, T., Wenzel, R. et al. Health-related quality of life and psychological distress among adults in Tanzania: a cross-sectional study. Arch Public Health 80, 144 (2022). https://doi.org/10.1186/s13690-022-00899-y
Timeline
Doctor of Philosophy - Medical Research in International Health
Ludwig Maximillian University (LMU)
2023.10 -
Research scientist
National Institute for Medical Research, Mbeya
2019.11 - Current
Master of Science - Public Health
University of South Wales
2019.05 - 2023.01
Intern doctor
Mbeya Zonal Referral Hospital
2017.11 - 2018.11
Doctor of Medicine - Medicine
Kilimanjaro Christian Medical University Colledge
2012.10 - 2017.10
A-Levels -
Kilakala girls secondary school
2010.04 - 2012.02